Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies ...

These data are meaningful both for the company’s efforts in Wilson ... If you are looking for a deeply undervalued AI stock that is more promising than PRME but that trades at less than ...

This data could potentially result in significant stock movement ... Begin your TipRanks Premium journey today. Prime Medicine, Inc. (PRME) Company Description: Prime Medicine Inc is a ...

Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY.

Equities researchers at Chardan Capital issued their FY2025 earnings per share estimates for Prime Medicine in a report issued on Monday, March 10th. Chardan Capital analyst G. Livshits anticipates ...

Shares of NYSE:PRME opened at $2.60 on Tuesday. The company has a 50 day moving average of $2.90 and a 200 day moving average of $3.59. The stock has a market cap of $341.02 million, a P/E ratio ...

This put 26.46% of the company's publicly available shares short. Short interest in Prime Medicine Corp (XNAS ... their positions without sending the stock sharply higher.

Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There is no Morningstar’s Analysis data available. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...